Janux Therapeutics, Inc.

The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings or other sources.

SEC original ↗Janux Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

agency bonds 400,924 400,924 Corporate debt securities 246,298 246,298 Commercial paper 157,203 157,203 Total short-term investments 943,145 138,720 804,425 Restricted cash: Money market account 816 816 Total restricted cash 816 816 Total assets measured at fair value on a recurring basis $ 956,984 $ 145,467 $ 811,517 $ 7 Table of Contents Janux Therapeutics, Inc.

SEC original ↗Janux Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

agency bonds 392,008 392,008 Corporate debt securities 317,168 317,168 Commercial paper 81,761 81,761 Total short-term investments 914,233 123,296 790,937 Restricted cash: Money market account 816 816 Total restricted cash 816 816 Total assets measured at fair value on a recurring basis $ 965,612 $ 165,197 $ 800,415 $ Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.

SEC original ↗Janux Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

agency bonds, corporate debt securities and commercial paper, all of which are highly rated by Moody s, S&P and Fitch.

SEC original ↗Janux Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

agency bonds 402,004 324 ( 1,404 ) 400,924 Corporate debt securities 246,056 298 ( 56 ) 246,298 Commercial paper 157,391 ( 188 ) 157,203 Total $ 945,450 $ 627 $ ( 2,932 ) $ 943,145 As of December 31, 2025 Amortized Unrealized Estimated Cost Gains Losses Fair Value U.

SEC original ↗Janux Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

agency bonds 389,831 2,195 ( 18 ) 392,008 Corporate debt securities 315,294 1,874 317,168 Commercial paper 81,720 47 ( 6 ) 81,761 Total $ 909,917 $ 4,349 $ ( 33 ) $ 914,233 The amortized cost and estimated fair value in the tables above exclude $ 6.2 million and $ 6.4 million of accrued interest receivable as of June 30, 2026 and December 31, 2025, respectively.

SEC original ↗Janux Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

“The recent expansion of our TRACTr, TRACIr, and ARM development programs displays our ability to enact a strategy that attempts to both maximize the benefit and value of our current clinical programs, including JANX007, while continuing to advance other differentiated candidates in oncology and autoimmune disease,” said David Campbell, Ph.

SEC original ↗Janux Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets.

SEC original ↗Janux Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Company has classified these investments as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investment securities as current assets.

SEC original ↗Janux Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.

SEC original ↗Janux Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

For a further list and description of the risks and uncertainties Janux faces, please refer to Janux’s periodic and other filings with the Securities and Exchange Commission, which are available at www.

SEC original ↗Janux Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Legal Proceedings 31 Item 1A.

SEC original ↗Janux Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Contingencies From time to time, the Company may be subject to claims or lawsuits arising in the ordinary course of business.

SEC original ↗Janux Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026